Gene editing has emerged as one of the most transformative technologies in biotech and pharma, with applications spanning therapeutics, diagnostics, research tools, and biomanufacturing. As CRISPR-based technologies, base editing, and prime editing advance, the industry has witnessed rapid commercialization, particularly with the approval of Casgevy and Lyfgenia in December 2023. But while the innovation story is exciting, here’s the question for sales and marketing teams:
How do you translate this trend into qualified leads and focused outreach?
BiopharmIQ analyzed over 330 gene editing companies worldwide and provided a quick snapshot of the sector to set the stage, then jumped into actionable tables listing out the major gene editing companies by region, including insights into what specific products/services each needs based on our industry-specific data. Read on if you work with gene editing companies and want to see which you should add to your CRM shortlist. This report gives you a strategic overview of the space and shows how to use BiopharmIQ to find contacts, track activity, and prioritize outreach, without wasting hours on manual research.
The data presented in this report utilized the BiopharmIQ platform, which tracks bio/pharma companies, including gene editing companies globally (academic/hospital/research centers were excluded from this analysis). While we strive for accuracy for our entire database and completeness for biopharma companies, there is a probability that some companies working in gene editing may not have been captured in this dataset. Moreover, our platform undergoes daily updates to add more companies, so the numbers may change. The data collection cut-off for this report is February 28, 2025.
The Big Picture: 330+ Companies, 23 Countries, and Still Growing
As of February 2025, BiopharmIQ identified 332 gene editing companies across 23 countries. The U.S. dominates with 217 companies — two-thirds of the global landscape — followed by China, the UK, Germany, and France (FIG. 1).
While North America remains the epicenter, Europe and Asia-Pacific are rapidly expanding. That means regional targeting is more important than ever, especially if your offering is specialized by market, compliance region, or distribution channel.
Global Distribution of Gene Editing Companies
- United States (217 companies) – Home to a vast majority of gene editing companies, particularly in biotech-heavy regions such as California and Massachusetts.
- China (30 companies) – A rapidly growing hub for gene editing, with companies focusing on therapeutic applications and CRISPR-based technologies.
- United Kingdom (16 companies) – A strong presence in genome editing tools and therapeutics, with notable companies like Cellectis and Oxford Genetics.
- Germany (13 companies) – Focused on gene editing for regenerative medicine and cell therapies.
- France (8 companies), Netherlands (7), Switzerland (5), and Ireland (5) – European countries with a growing presence in CRISPR technologies and gene-edited therapies
Other key contributors include South Korea, Singapore, Japan, and Canada, each with at least two or more gene editing companies making advances in the field.
A full list of 330+ gene editing companies can be found here.
U.S. Hotspots: Where the Action Is
Within the U.S., two states — California and Massachusetts — account for over 60% of all gene editing companies. These hubs are home to major players like Beam Therapeutics, Editas Medicine, Mammoth Biosciences, and Synthego.
But other states are emerging fast. New York, Pennsylvania, Maryland, Texas, and North Carolina all support clusters of companies with increasing demand for tools, services, and partnerships.
Top U.S. States for Gene Editing Companies
- California (68 companies) – The largest biotech hub in the U.S., home to key players such as Inscripta, Synthego, and Mammoth Biosciences, driving CRISPR research and commercialization.
- Massachusetts (63 companies) – A powerhouse in gene editing, home to Editas Medicine, Beam Therapeutics, and Intellia Therapeutics, supported by a strong academic ecosystem from Harvard and MIT.
- New York (15 companies) – Hosts growing startups like Century Therapeutics, benefiting from New York’s major research institutions and hospital networks.
- Pennsylvania (10 companies), North Carolina (7), Maryland (7), and Texas (6) – Emerging biotech hubs with strong investment in gene editing innovation.
Sales takeaway: If you’re building a territory plan or prioritizing in-person visits and outbound campaigns, this state-level data gives you a starting point.
Not All Gene Editing Companies Are Alike
It’s not enough to know where a company is. You need to know what they’re likely to buy. We categorize companies into four main segments:
Therapeutic developers (205 companies)
The largest segment, focused on gene-editing-based treatments for oncology, rare diseases, and regenerative medicine. Key players include Beam Therapeutics, CRISPR Therapeutics, Editas Medicine, and Prime Medicine. These companies are working on gene-edited treatments, often in early clinical stages. They tend to need:
- CDMO partners
- Delivery platforms
- Regulatory support
- Clinical CROs
Vendors (104 companies)
Companies providing gene editing reagents, tools, and services for research and clinical applications. Leading vendors include Synthego, Integrated DNA Technologies (IDT), and GenScript. They may be:
- OEM customers for your lab equipment
- Targets for software or automation systems
- Candidates for co-marketing or distribution deals
Contract Research & Manufacturing (19 companies)
These CDMOs support therapeutics and vendors. Key players include Aldevron, ElevateBio, and Oxford Genetics. Think:
- Biomanufacturing solutions
- Quality testing tools
- Workforce and lab expansion services
Diagnostics (4 companies)
A small but emerging segment focused on CRISPR-powered tests. Developing CRISPR-based diagnostic tools for genetic and infectious diseases. Notable companies include Sherlock Biosciences, Precede Biosciences, Avellino AI, and DNAiTECH. Ideal customers for:
- AI/ML tools
- Hospital partnerships
- Sample prep or sequencing technologies
Sales takeaway: Your pitch will land better when it matches their segment-specific pain points. A diagnostic company doesn’t need the same offering as a preclinical therapeutic, and BiopharmIQ makes it easy to distinguish between them.
From the Author: How to Use BiopharmIQ for Sales Execution
BiopharmIQ didn’t just build a list — they built a toolkit.
How to Filter This List Based on Your Offering:
- Sell reagents? → Filter by vendors and early-stage therapeutics
- Offer clinical trial services? → Filter by therapeutics in Phase I/II
- Sell manufacturing equipment? → Filter by Contract Reasearch & Manufacturing and vendors with >50 employees
Use BiopharmIQ filters like employee size, segment, funding activity, and location to build your best-fit list in minutes, not weeks!
If you’re in:
- Clinical trial services → focus on early-stage therapeutic companies in MA and CA
- Lab equipment or automation → target growing vendors with >50 employees
- Consulting or regulatory services → look for companies entering IND-enabling stages
- Software platforms for CRO/CDMO ops → aim for CDMOs in the U.S. and EU hubs
Once you identify a company in your region or category of interest, here’s what you can do next inside BiopharmIQ:
- Use the Contact Search module to find decision-makers by title, function, and seniority.
- Track their latest funding rounds with our Funding Activity tool — perfect for timing your outreach.
- Use the Hot Leads module to identify companies that have raised money, expanded headcount, or entered trials — all signals that they’re ready to buy.
- Set free alerts to get notified when companies in your vertical move, grow, or make headlines.
Whether you’re building a prospecting list or managing an account portfolio, BiopharmIQ gives you visibility across companies, markets, and buyers.
Final Word: From Landscape to Laser Focus
The gene editing industry continues to grow, with 332 identified companies globally, most based in the U.S., followed by China and the UK. While therapeutics lead the field, the broader ecosystem includes CDMOs, vendors, and diagnostics companies that are essential to scaling innovation. While therapeutic applications currently drive much of the momentum, the broader ecosystem is equally important. Vendors and CDMOs play a critical role in supporting research, development, and commercialization. As more programs enter clinical trials and regulatory frameworks evolve, we can expect this landscape to become even more dynamic.
For professionals in sales, marketing, and business development, this presents a unique opportunity: to understand the needs of these companies, anticipate market shifts, and engage strategically. Staying informed and aligned with where the industry is heading will be key to building meaningful partnerships across the gene editing value chain.
For a deeper dive, you can download BiopharmIQ's full-length, comprehensive report on 330+ gene editing companies. Check out their Current Landscape of Gene Editing Companies white paper or contact us at marketing@biopharmIQ.com.
